REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, located at Terranea Resort, Rancho Palos Verdes, CA. The second is the Barclays Sixth Annual Gene Editing/Therapy Summit on November 14, 2022, where REGENXBIO will discuss AAV Gene Therapy's current status and future direction at 2:50 p.m. ET. The company focuses on advancing AAV Therapeutics with its proprietary NAV Technology Platform, emphasizing its goal of progressing five products to pivotal-stage or commercial status by 2025.

ROCKVILLE, Md., Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Credit Suisse 31st Annual Healthcare Conference
Date: Tuesday, November 8, 2022
Location: Terranea Resort, Rancho Palos Verdes, CA

Barclays Sixth Annual Barclays Gene Editing/Therapy Summit
Date: November 14, 2022
Panel Title: AAV Gene Therapy – Current Status and Future Direction
Panel Time: 2:50 p.m. ET

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301665884.html

SOURCE REGENXBIO Inc.

FAQ

What conferences is REGENXBIO participating in November 2022?

REGENXBIO is participating in the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, and the Barclays Sixth Annual Gene Editing/Therapy Summit on November 14, 2022.

When does REGENXBIO's participation at the Barclays Summit begin?

REGENXBIO's panel discussion at the Barclays Sixth Annual Gene Editing/Therapy Summit is scheduled for November 14, 2022, at 2:50 p.m. ET.

What is REGENXBIO's NAV Technology Platform?

REGENXBIO's NAV Technology Platform is a proprietary adeno-associated virus (AAV) gene delivery system that supports the development of various gene therapies.

What is REGENXBIO's goal by 2025?

REGENXBIO aims to advance five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Where will the Credit Suisse Healthcare Conference be held?

The Credit Suisse 31st Annual Healthcare Conference will be held at Terranea Resort in Rancho Palos Verdes, CA.